Impaired health-related quality of life predicts progression of disability in multiple sclerosis

European Journal of Neurology

Volumn 20, Issue 1, 2013, Pages 79-86

  Benito Leon J ^a,b,c   Mitchell, A J ^d   Rivera Navarro, J ^e   Morales Gonzalez J M ^f  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e UNIVERSITY OF SALAMANCA   (Spain)

^f Ministry of Health   (Spain)

Author keywords

Disability course; Health related quality of life; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; INTERFERON BETA SERINE;

ADULT; AGED; ARTICLE; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT INVENTORY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; COHORT STUDIES; DISABILITY EVALUATION; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; QUESTIONNAIRES; SPAIN; YOUNG ADULT;

EID: 84871644228     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03792.x     Document Type: Article

References (35)

1. Benito-Leon J, Morales JM, Rivera-Navarro J, Mitchell A. A review about the impact of multiple sclerosis on health-related quality of life. Disabil Rehabil 2003; 25: 1291-1303.
2. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol 2005; 4: 556-566.
3. Nortvedt MW, Riise T. The use of quality of life measures in multiple sclerosis research. Mult Scler 2003; 9: 63-72.
4. Miller DM, Allen R. Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice. Curr Neurol Neurosci Rep 2010; 10: 397-406.
5. Benito-Leon J, Louis ED, Rivera-Navarro J, Medrano MJ, Vega S, Bermejo-Pareja F. Low morale is associated with increased risk of mortality in the elderly: a population-based prospective study (NEDICES). Age Ageing 2010; 39: 366-373.
6. Benito-Leon J, Louis ED, Bermejo-Pareja F, Neurological Disorders in Central Spain Study G. Population-based case-control study of morale in Parkinson's disease. Eur J Neurol 2009; 16: 330-336.
7. Martinez-Martin P, Benito-Leon J, Alonso F, Catalan MJ, Pondal M, Zamarbide I. Health-related quality of life evaluation by proxy in Parkinson's disease: approach using PDQ-8 and EuroQoL-5D. Mov Disord 2004; 19: 312-318.
8. Benito-Leon J, Cubo E, Coronell C, on behalf of the ASG. Impact of apathy on health-related quality of life in recently diagnosed Parkinson's disease: the ANIMO study. Mov Disord 2012; 27: 211-218.
9. Benito-Leon J, Morales JM, Rivera-Navarro J. Health-related quality of life and its relationship to cognitive and emotional functioning in multiple sclerosis patients. Eur J Neurol 2002; 9: 497-502.
10. Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life as a predictor for change in disability in MS. Neurology 2000; 55: 51-54.
11. Visschedijk MA, Uitdehaag BM, Klein M, et al. Value of health-related quality of life to predict disability course in multiple sclerosis. Neurology 2004; 63: 2046-2050.
12. Drulovic J, Riise T, Nortvedt M, Pekmezovic T, Manigoda M. Self-rated physical health predicts change in disability in multiple sclerosis. Mult Scler 2008; 14: 999-1002.
13. Guarnaccia JB, Aslan M, O'Connor TZ, et al. Quality of life for veterans with multiple sclerosis on disease-modifying agents: relationship to disability. J Rehabil Res Dev 2006; 43: 35-44.
14. Renoux C. Natural history of multiple sclerosis: long-term prognostic factors. Neurol Clin 2011; 29: 293-308.
15. Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 2009; 5: 672-682.
16. Cella DF, Dineen K, Arnason B, et al. Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996; 47: 129-139.
17. Rivera-Navarro J, Benito-Leon J, Morales-Gonzalez JM. [Searching for more specific dimensions for the measurement of quality of life in multiple sclerosis]. Rev Neurol 2001; 32: 705-713.
18. Chang CH, Cella D, Fernandez O, et al. Quality of life in multiple sclerosis patients in Spain. Mult Scler 2002; 8: 527-531.
19. Morales-Gonzales JM, Benito-Leon J, Rivera-Navarro J, Mitchell AJ, Group GS. A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study. Mult Scler 2004; 10: 47-54.
20. Rivera-Navarro J, Morales-Gonzalez JM, Benito-Leon J, Madrid Demyelinating Diseases G. Informal caregiving in multiple sclerosis patients: data from the Madrid Demyelinating Disease Group study. Disabil Rehabil 2003; 25: 1057-1064.
21. Rivera-Navarro J, Morales-Gonzalez JM, Benito-Leon J, Mitchell AJ. [The social and familial dimension: experiences of caregivers and people with multiple sclerosis. The GEDMA study]. Rev Neurol 2008; 47: 281-285.
22. Olazaran J, Cruz I, Benito-Leon J, Morales JM, Duque P, Rivera-Navarro J. Cognitive dysfunction in multiple sclerosis: methods and prevalence from the GEDMA Study. Eur Neurol 2009; 61: 87-93.
23. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
24. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
25. Villar LM, Sadaba MC, Roldan E, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005; 115: 187-194.
26. Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002; 15: 257-266.
27. Myhr KM, Riise T, Vedeler C, et al. Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension. Mult Scler 2001; 7: 59-65.
28. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006; 63: 1686-1691.
29. Bejarano B, Bianco M, Gonzalez-Moron D, et al. Computational classifiers for predicting the short-term course of Multiple sclerosis. BMC Neurol 2011; 11: 67.
30. Benito-Leon J, Martinez-Martin P. [Health-related quality of life in multiple sclerosis]. Neurologia 2003; 18: 210-217.
31. Smedal T, Beiske AG, Glad SB, et al. Fatigue in multiple sclerosis: associations with health-related quality of life and physical performance. Eur J Neurol 2011; 18: 114-120.
32. Modrego Pardo PJ, Latorre MA, Lopez A, Errea JM. Prevalence of multiple sclerosis in the province of Teruel, Spain. J Neurol 1997; 244: 182-185.
33. Benito-Leon J, Martin E, Vela L, et al. Multiple sclerosis in Mostoles, central Spain. Acta Neurol Scand 1998; 98: 238-242.
34. Mowry EM, Beheshtian A, Waubant E, et al. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology 2009; 72: 1760-1765.
35. Gold SM, Schulz H, Monch A, Schulz KH, Heesen C. Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler 2003; 9: 404-410.